Participation à des congrès scientifiques

Présentations orales

Les résultats de nombreux travaux de l’écosystème Experts Recherche Lymphome font l’objet de présentations orales lors des congrès scientifiques de référence. Parmi ces congrès figurent notamment ceux de The American Association of Clinical Oncology, de The European Hematology Association et de la Société Française d’Hématologie.

Liste mise à jour le 01/07/2021

Parmi les communications orales récentes, nous pouvons citer :

  • Early Positron Emission Tomography Response-Adapted Treatment in Localized Diffuse Large B-Cell Lymphoma (aaIPI=0): Results of the Phase 3 LYSA LNH-09-1B Trial – Serge Bologna
  • Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA – Charles Herbaux
  • First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, The French real-life database for CAR-T cells in hematologic malignancies – Steven Le Gouill
  • Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study) – Catherine Thieblemont
  • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL): clinico-pathological analysis of a multicenter European cohort – Doriane Cavalieri
  • Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients : a LYSA study – Vincent Camus

Posters

Les résultats des travaux de l’écosystème Experts Recherche Lymphome peuvent aussi être présentés sous la forme de posters.

Liste mise à jour le 01/07/2021

Parmi les posters LYSA récents, nous pouvons citer :

  • CNS Relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL – Catherine Thieblemont
  • Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA – Charles Herbaux
  • Prospective Evaluation of Lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA Group – Yassine Al Tabaa
  • Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Marginal Zone Lymphoma: primary analysis of a phase 2 trial from LYSA – Charles Herbaux
  • Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Follicular Lymphoma: primary analysis of a phase 2 trial from LYSA – Guillaume Cartron
  • Circulating tumor DNA load and total metabolic tumor volume in Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOP – From REMARC, a LYSA study – Catherine Thieblemont
  • High adipose tissue density is a negative prognostic factor in DLBCL patients treated by R-CHOP, independent from TMTV and PS – From the REMARC study – Catherine Thieblemont
  • Selinexor in Combination with R-GDP for Patients with Relapsed/ Refractory B-Cell Lymphoma: Preliminary results of the SELINDA phase Ib LYSA study – Marie Maerevoet
  • Long-term outcomes of elderly patients treated with frontline R-CHOP: Update of the LNH03-6B trial – Vincent Camus
  • Impact of DUSP22 rearrangement on the prognosis of systemic ALK-negative anaplastic large cell lymphoma : a LYSA and TENOMIC study – David Sibon
  • Brentuximab vedotin as consolidation treatment in patients with stage I/II classical Hodgkin’s lymphoma and a positive FDG-PET after 2 cycles of ABVD : a LYSA phase 2 study – Thomas Gastinne
  • Gender disparities in quality of life of French patients one year after the diagnosis of Lymphoma, a LYSA study – Caroline Besson